Power Law company profile

MyoKardia

Biotech & Life Sciences · San Francisco, United States · Founded 2012 · IPO 2015 Decacorn

Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases

Valuation

$13B

Market cap · 2026

Revenue

$26M

Latest reported FY

Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

6 investors on MyoKardia's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

Sanofi

Cormorant Asset Management

BridgeBio

Third Rock Ventures

Casdin Capital

Cowen Group

MyoKardia mafia

Startups founded by MyoKardia alumni

Former MyoKardia employees who went on to start their own companies. Sorted by Dealroom signal score.

ProlaioEst. 2022

Jay EdelbergUnited States

Signal score92

BridgeBioEst. 2014

Neil KumarUnited States

Signal score90

AlumisEst. 2021

June LeeUnited States

Signal score90

HealthExEst. 2022

Priyanka Agarwal, MD, MBAUnited States

Signal score89

Maze TherapeuticsEst. 2018

Eric GreenUnited States

Signal score79

WithMe HealthEst. 2018

Ash DamleUnited States

Signal score61

KardiganEst. 2023

TGTassos GianakakosUnited States

Signal score59

Book a demo to explore the full alumni network →

Global footprint

Where MyoKardia has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Patent intelligence

$57M patent portfolio · 33 active families

Estimated portfolio value

$57M

0.44% of market cap · 123.7× smaller than top peer Janssen Vaccines ($7.1B)

33 active patent families

Where MyoKardia innovates CardiomyopathyPharmacologyHypertrophic cardiomyopathyLeft VentriclesPyrimidine

Where MyoKardia concentrates vs peers

Each axis is a top-10 topic across MyoKardia and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about MyoKardia

An AI-synthesized read of the highest-engagement posts about MyoKardia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MyoKardia on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles